Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

ORYZON

  • CARLOS BUESA-ARJOL, ORYZON

Oryzon (ORY.MC) is a public company listed in the Madrid and part of the IBEX-Small Cap Index. It is now one of the most liquid companies in this segment of the market. Oryzon is clinical stage Biopharmaceutical Company that, with its Epigenetic Platform, develops first-in-class drugs for diseases with strong unmet medical need such as cancer and neurodegenerative diseases. Oryzon’s pipeline includes inhibitors against Histone demethylases, with a strong specialization in KDM1A (LSD1).

Oryzon is leading epigenetics in CNS with Vafidemstat, a brain penetrant dual LSD1-MAOB inhibitor being explored on three different Phase IIA trials: in mil-moderate AD; in a basket trial in aggressivity covering three different psychiatric indications like like ASD, ADHD and BLP and a third one in RR/SP-MS. Oryzon has also an oncology program, iadademstat, this is a highly selective LSD1 inhibitor being explored in two Phase IIA trials, one in AML and the other in SCLC in a biomarker guided trial.

  • Date:Monday, February 11
  • Time:2:45 PM - 3:00 PM
  • Room:Hudson/Empire
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Submission ID:23534
  • Goal for Presentation:To raise the awareness of our company among US investors
  • Company Website:WWW.ORYZON.COM
  • Company HQ City:Barcelona
  • Company HQ Country:Spain
  • Market Cap:120m USD
  • Ticker:ORY
  • Exchange:Madrid Stock Exchange
  • CEO/Top Company Official:Carlos Buesa-Arjol
  • Year Founded:2000
  • Main Therapeutic Focus:CNS/Neurological
  • Lead Product in Development:Vafidemstat
  • Development Phase of Primary Product:Phase II
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):two
Speakers
CARLOS BUESA-ARJOL
ORYZON
Back